Plexium

Plexium, Inc. is a biotechnology company developing precision medicines through targeted protein degradation, an approach designed to address disease-causing proteins. The company focuses on the rational design and discovery of Monovalent Direct Degraders and Molecular Glues, using small-molecule compounds intended as potential first-in-class or best-in-class treatments for serious conditions with high unmet medical needs.

Plexium’s research and development is powered by DELTA Discovery™, its proprietary AI-integrated phenotypic and functional drug discovery platform. The platform has supported the advancement of multiple protein degraders into clinical development, while the company’s enabling technologies aim to expand the range of targets that can be pursued through protein degradation and related approaches. Its pipeline includes clinical-stage programs, including a program focused on SMARCA2, and the company provides information about its clinical trials, scientific publications, and presentations.

Based in San Diego, Plexium brings together expertise across biology, chemistry, medicine, and drug development. Its collaborative team is guided by a commitment to developing potentially transformative medicines for patients in need.